American Oriental Bioengineering

American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of pharmaceutical and healthcare products. The company is headquartered in Shenzhen, Guangdong and currently employs 3,719 full-time employees. The company went IPO on 2006-12-18. The firm is engaged in development, manufacture and commercialization of a broad range of pharmaceutical and healthcare products. The Company’s business consists of prescription pharmaceutical products, over-the-counter pharmaceutical products and nutraceutical products. Two flagship prescription pharmaceutical products marketed in China are Shuanghuanglian Lyophilized Injection Powder, or SHL Injection Powder, and Cease Enuresis Soft Gel, or CE Gel. Over-the-counter pharmaceutical products are similar to its prescription pharmaceutical products in that they need approval from the SFDA. Nutraceutical products are intended for the overall well-being. The firm also sells several nutraceutical products, including its soybean peptide-based drinks, tablets, powder and instant coffee.